CRF1 Receptors as a Therapeutic Target for Irritable Bowel Syndrome

E-ISSN： 1873-4286|12|31|4071-4088

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.12, Iss.31, 2006-01, pp. : 4071-4088

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Protease-activated receptors: potential therapeutic targets in irritable bowel syndrome?

By Gloro Romain Ducrotte Philippe Reimund Jean-Marie

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 5, 2005-10 ,pp. : 1079-1095

Informa Healthcare

Access to resources Recommend Favorite

A review of irritable bowel syndrome and an update on therapeutic approaches

By Bassett John T Cash Brooks D

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 7, 2008-05 ,pp. : 1129-1143

Informa Healthcare

Access to resources Recommend Favorite

Irritable bowel syndrome: an update on therapeutic modalities

By Farhadi Ashkan Bruninga Keith Fields Jeremy Keshavarzian Ali

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 7, 2001-07 ,pp. : 1211-1222

Informa Healthcare

Access to resources Recommend Favorite

Irritable Bowel Syndrome: Recent and Novel Therapeutic Approaches

By Andresen Viola Camilleri Michael

Drugs, Vol. 66, Iss. 8, 2006-01 ,pp. : 1073-1088

Adis International

Access to resources Recommend Favorite

Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome

Mini Reviews in Medicinal Chemistry, Vol. 16, Iss. 18, 2016-12 ,pp. : 1462-1469

Bentham Science Publishers

Access to resources Recommend Favorite